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Abstract
Introduction: Despite the therapeutic beneﬁ ts of drugs, adverse drug reactions (ADRs) occur. Method: We assessed a series of 
suspected ADRs identiﬁ ed from notiﬁ cations and intensive monitoring of inpatients from March 2013 to March 2014. Results: 
Skin reactions predominated (31%). Systemic anti-infective agents were implicated in 16 (72%) reactions. Fifteen (68%) ADRs 
were classiﬁ ed as possible. The implicated drug was not correctly identiﬁ ed by the healthcare team in 12 cases. Conclusions: 
Some reactions were not correctly attributed to the causative drug(s), suggesting that the use of a validated evaluation method 
can promote successful identiﬁ cation of causal links between ADRs and drugs. 
Keywords: Adverse drug reactions. Pharmacovigilance. Hospitals.
Drugs are crucial therapeutic tools, and ensuring access to 
their use is a global priority. However, drugs also carry the risk 
of adverse reactions. Since the thalidomide tragedy in 1960, 
countries have sought to implement pharmacovigilance systems 
and have conducted studies to prevent or minimize adverse drug 
reactions (ADRs), thereby reducing the huge impact these events 
can have on morbidity and mortality rates and on healthcare 
costs(1) (2). Questions on whether responses to drugs and the 
occurrence of ADRs are inﬂ uenced by factors such as ethnicity 
remain unanswered, calling for local pharmacoepidemiologic 
studies to feed the World Health Organization (WHO) 
notiﬁ cation system in Uppsala. Furthermore, national or regional 
level data have educational value and can guide the formulation 
of national level regulatory measures(3) (4).
In 2013, the Brazilian Health Surveillance Agency [Agência 
Nacional de Vigilância Sanitária (ANVISA)] issued regulations 
to improve patient safety in healthcare services, decreeing that 
adverse event notiﬁ cations and monitoring be employed to 
reduce risks among inpatients(5). By detecting and evaluating 
ADR causality  ̶̶̶  a key procedure in pharmacovigilance  ̶̶̶ 
risk-beneﬁ t assessment of drugs can be conducted for speciﬁ c 
populations, triggering warnings from global pharmacovigilance 
systems and ultimately reducing exposure risks by adjusting 
drug dosages(6). The present study sought to describe the 
occurrence of ADRs in adults hospitalized with infectious 
diseases at a Brazilian teaching hospital and to establish causal 
links with the drugs administered. 
Adverse drug reactions identiﬁ cation was based on data 
collected from suspected ADR notiﬁ cation forms, drug-therapy 
follow-up reports, medical records, laboratory tests, and 
hospital prescriptions. The patients included in the study were 
adults treated by the infectology team of the Universidade de 
Brasília teaching hospital between 1 March 2013 and 31 March 
2014. Patients hospitalized for less than 48h and those with no 
medical records available were excluded. The following data 
were collected: patient identiﬁ cation; description of suspected 
ADR; onset and duration of the event; daily dose, administration 
route, administration period, and rationale for prescription of 
the implicated drug; other drugs prescribed; protocol followed 
for ADR management; clinical evolution; and information on 
re-exposure to the implicated drug. ADR diagnosis was based 
on the deﬁ nition proposed by the World Health Organization 
(WHO), i.e., any harmful or undesirable and unintended 
response occurring with drugs in dosages typically used in 
humans for prophylaxis, diagnosis, or treatment of diseases or 
for altering physiologic functions(1).
The Naranjo algorithm(6) was employed to establish causal 
links between suspected ADRs and drugs. The descriptions 
of suspected ADRs were harmonized with the WHO Adverse 
Drug Reaction Terminology. The approaches adopted by the 
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TABLE 1
Characteristics of patients hospitalized for infectious diseases at the Universidade de Brasília teaching hospital between March 2013 and March 2014.
Characteristics All patients Patients with ADRs
Patients enrolled 113 13
Males n (%) 76 (67) 9 (69)
Age (years: mean ± SD) 43 ± 17.1 37 ± 14.3
>60 years ( n) 16 1
HIV-infected ( n) 50 5
On ART ( n) 40 3
Length of hospital stay (days: mean ± SD) 12 ± 10.2 25 ± 21.7
Length of hospital stay (days: median, range) 9 (2–81) 19 (2–77)
ADR: adverse drug reaction; SD: standard deviation; HIV: human immunodeﬁ ciency virus ART: antiretroviral therapy.
multiprofessional team were categorized as drug withdrawal 
followed by no reaction improvement, drug withdrawal followed 
by reaction improvement, continued drug administration, 
dosage modiﬁ cation, and need for symptomatic treatment. 
Identiﬁ cation of suspected events drew on the following sources: 
Brazilian National Formulary (Formulário Terapêutico Nacional
2010)(7), Micromedex Solutions (Truven Health Analytics) (8), 
and Meyler’s Side Effects of Drugs: The International 
Encyclopedia of Adverse Drugs Reactions and Interactions (9). 
Investigation of causal links was not limited to the drug initially 
identified, but extended to other drugs having a possible 
temporal relationship with the suspected ADR. The organs and 
physiologic systems affected were identiﬁ ed and all suspected 
ADRs were categorized as type A or B, according to Rawlins 
and Thompson (10). The Anatomical Therapeutic Chemical (ATC) 
classiﬁ cation(11) was applied to categorize the drugs implicated 
in suspected events. 
The study included 113 patients: 67% (n = 76) were men; 
the mean age was 43 years; and 44% (n = 50), were human 
immunodeﬁ ciency virus (HIV) infected. The mean length of 
hospital stay was 12 days (Table 1). Fourteen (12%) patients 
were hospitalized more than once, 15 (13%) had changes in 
the level of treatment complexity, and four (3.5%) died during 
the study period. Twenty-two suspected ADRs were identiﬁ ed 
in 13 (12%) patients (1.7 ADR per patient). The mean length 
of hospital stay for these patients was 25 days (Table 1). Skin 
(31%), hepatobiliary (18%), and gastrointestinal reactions (18%) 
predominated. Pruritus (22%), changes in liver function (13%), 
and nausea/vomiting (13%) were the most common symptoms 
experienced. Twenty-one 95%) of the events (were Type A 
ADRs; one reaction (cutaneous hyperpigmentation related to 
polymyxin B) was categorized as type B.
The suspected drug was withdrawn in 14 (63%) cases and 
continued in six (27%); information on ADR management was 
lacking for two events. Symptomatic treatment was initiated 
in seven cases (after drug withdrawal in four). Three events 
required intensive monitoring using laboratory tests. Of the 
patients affected, 11 (84%) recovered without sequelae and two 
died of unrelated causes. Fifteen drugs were implicated, ten 
(66%) of which were systemic anti-infectives (J01, J02, J05) 
and four (26%) were drugs acting on the central nervous system 
(N02, N03). Among the anti-infective agents, polymyxin B and 
sulfamethoxazole-trimethoprim were each connected with four 
events. Among exposed patients, polymyxin B accounted for 
most suspected cases (Table 2). 
Causal links with the drug initially implicated were 
established as suspected in 22 events, probable in six (27%), 
possible in 15 (68%), and uncertain in one (5%). In the six 
cases having a probable causal link with the drug initially 
reported (Naranjo scores of 5 or higher), the additional drugs 
administered had lower scores (possible ADR) (Table 3). In 
the 15 events with possible causal links, 99 other drugs were 
administered. The drug initially reported scored higher than the 
other drugs administered in only one event. In all remaining 
cases, the other drugs scored the same or higher than that initially 
reported as causing the reaction. 
Fourteen (64%) reactions were identiﬁ ed from notiﬁ cation 
forms and eight (36%) from clinical records, indicating 
underreporting of ADRs. Employing both strategies allows 
ADR frequencies to be more accurately estimated, and entails 
the surveying of cases during patient follow-up by professionals 
with pharmacovigilance training. Intensive monitoring and 
review of medical records were also employed by Menezes 
et al.(12) Lobo et al.(13) used incentives to promote spontaneous 
notiﬁ cation, associated with intensive monitoring of medical 
records and laboratory tests. Miguel et al.(14) compared intensive 
monitoring with retrospective searching of databases, ﬁ nding 
the latter method to be less costly.
In the present study, the ADR incidence was 11.5%. In a 
systematic review of 29 studies, Cano et al.(2) observed that 
ADRs occurred in 1.6-41.4% of inpatients, with rates of 1.7-51.8 
events per 100 hospitalizations. In another systematic review, 
Miguel et al.(14) found that ADRs occurred in 16.9% of inpatients, 
but this rate may have been biased by population heterogeneity 
and the methods employed. Secondary data from the Brazilian 
Hospital Information System revealed an ADR prevalence 
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TABLE 2
Drugs implicated in suspected ADRs among patients hospitalized for infectious diseases at the Universidade de Brasília 
teaching hospital between March 2013 and March 2014.
   Patients  Patients  ADRs per exposed 
Drug ATC ADRs affected exposed patient (× 100)
Sulfamethoxazole + trimethoprim J01EE01 4 4 36 11.1
Polymyxin B J01XB02 4 2 2 200.0
Ceftriaxone J01DD04 1 1 31 3.2
Sulfadiazine J01EC02 1 1 9 11.1
Oxacillin J01CF04 1 1 8 12.5
Fluconazole J02AC01 1 1 30 3.3
Liposomal amphotericin B J02AA01 1 1 7 14.3
Ganciclovir J05AB06 1 1 4 25.0
Atazanavir J05AE08 1 1 7 14.3
Ritonavir J05AE03 1 1 26 3.8
Tramadol N02AX02 2 1 16 12.5
Paracetamol N02BE01 1 1 14 7.1
Carbamazepine N03AF01 1 1 5 20.0
Gabapentin N03AX12 1 1 2 50.0
Lactulose A06AD11 1 1 8 12.5
ADR: adverse drug reaction; ATC: anatomical therapeutic chemical classiﬁ cation.
TABLE 3
Evaluation of ADR causality in patients hospitalized for infectious diseases at the Universidade de Brasília teaching hospital 
between March 2013 and March 2014.
Adverse drug reaction Suspected drug Naranjo score  Causality Other drugs Naranjo score  Causality
Elevated serum creatinine Polymyxin B 7 Probable Meropenem 3 Possible
    Tigecycline 2 Possible
    Heparin 2 Possible
    Promethazine 2 Possible
Paresthesia Polymyxin B 7 Probable Amlodipine 3 Possible
    Tigecycline 2 Possible
    Heparin 2 Possible
    Meropenem 2 Possible
    Promethazine 2 Possible
Pruritus Polymyxin B 5 Probable Amlodipine 3 Possible
    Meropenem 3 Possible
    Promethazine 3 Possible
    Tigecycline 2 Possible
    Heparin 2 Possible
Anemia Sulfamethoxazole + trimethoprim 5 Probable Prednisone 3 Possible
    Omeprazole 3 Possible
    Fluconazole 2 Possible
Nausea and vomiting Ritonavir 7 Probable - - -
Diarrhea Lactulose 7 Probable Meropenem 3 Possible
    Vancomycin 3 Possible
    Ranitidine 3 Possible
    Liposomal amphotericin B 2 Possible
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of 1.8 per 1,000 hospitalizations. According to the investigators, 
all inpatients in the sample were at risk, given the widespread 
use of drug therapy in hospitals(15).
In the present study, 31% of suspected ADRs affected the 
skin, while 18% impacted hepatobiliary functions and another 
18% altered gastrointestinal functions. Similarly, Menezes 
et al.(12) found a predominance of cutaneous rash (20%), pruritus 
(13%), and hyperemia (12%) among ADRs, while Rozenfeld 
et al. (15) reported ADRs predominantly affecting the 
gastrointestinal tract (55%) and central nervous system (22%). 
Dermatologic reactions are described as the most frequent type 
in a number of studies, partially because these ADRs are more 
promptly identiﬁ ed(16). In the present study, type A reactions 
accounted for 95% of the suspected cases. Similar results have 
been reported elsewhere(13) (17). The only reaction classiﬁ ed as 
type B in the present study was a case of skin hyperpigmentation 
associated with polymyxin B   ̶̶̶  a rarely reported ADR(18).
Of the patients with suspected ADRs, 84% recovered without 
sequelae and two (16%) died of other causes. Similar results 
were obtained elsewhere in Brazil. In a study by Noblat et al.(17), 
the outcomes of ADRs included 90.6% recoveries, 6.1% deaths 
from other causes, 2.8% unknown outcomes, and 0.5% deaths 
from ADRs. In an investigation by Rozenfeld et al(15), 84.1% of 
patients with ADRs were discharged. 
In the present study, an association was found between length 
of hospital stay and ADR occurrence: patients with longer stays 
had a greater number of reactions. Involvement of anti-infective 
agents in the majority of suspected ADRs was an expected 
feature, as all patients had an infectious disease and there was a 
high prevalence of immunosuppression. This pattern, however, 
was not observed for drugs acting on the central nervous system, 
prescribed for few patients in the present study. A number of 
studies have reported an association between ADRs and anti-
infective agents(12) (13) (17), as well as between ADRs and drugs 
acting on the central nervous system(12) (13).
Using the Naranjo algorithm, most reactions described in the 
present study were classiﬁ ed as possible. Similar results were 
found by other investigators. Causality was investigated for all 
drugs having a temporal relationship with the reaction. Few 
studies, however, have applied the Naranjo algorithm to additional 
medications given to patients. In a study by Danza et al.(19), nearly 
half of ADRs were related to drug interactions, a factor that 
increases the risks of type A reactions. The Naranjo algorithm 
proved highly speciﬁ c, establishing causal links when causality 
criteria were clearly met  ̶̶ ̶ i.e., the algorithm correctly identiﬁ ed 
patients with high scores (who developed ADRs) and those with 
very low scores (without ADRs). However, when criteria were not 
readily met or when variables could not easily be distinguished, the 
algorithm displayed low sensitivity, failing to clearly distinguish 
causal links. Categorization of a reaction as possible indicated that 
the healthcare team failed to identify the drugs responsible for the 
reaction, since the drug initially suspected had a lower score than 
other medications administered.
In most studies, the number of ADRs identified from 
notification system databases tends to be low, but can be 
enhanced by additional techniques, such as intensive monitoring 
or use of ADR surveillance software. Encouraging healthcare 
professionals to record iatrogenic events is crucial for obtaining 
valid data. In a review of ADR prevention methods, Rommers(20) 
found that participation of a clinical pharmacist in patient visits 
and use of computer-based prescribing are among the most 
employed strategies. The relevance of engaging pharmacists 
in ADR prevention has also been emphasized by other 
investigators.
The ADR proﬁ le identiﬁ ed in the present study and the ﬁ nding 
that some of these reactions failed to be correctly attributed to the 
causative drugs suggest that employing a validated evaluation 
method promotes the successful identiﬁ cation of causal links 
between adverse reactions and drugs.
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